Michael S. Exton, Ph.D.

Michael S. Exton, Ph.D.

Chief Executive Officer and DirectoratLexicon Pharmaceuticals· In proxies 2024–2025

Pay in FY2025+25% from the year before · Lexicon Pharmaceuticals stock +55.7% the same year

Michael S. Exton, Ph.D. was paid $3.6M in FY2025 (Dec), up 25%. Lexicon Pharmaceuticals stock rose 55.7% that year.

Pay$100 in the stock at the end of FY23 → $75
Pay is from the Summary Compensation Table of each Lexicon Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Lexicon PharmaceuticalsPublic company · 2 yr
    • Chief Executive Officer and Director2024 – Present · 2 yrStock in role +5%

Roles come from the proxy statements of each company.

Boards1

  • Lexicon PharmaceuticalsDirector · 1 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?